Starting patients on a targeted treatment | See abbv.ie/ElaherePI

Please see https://www.abbv.ie/ElaherePI for Full Prescribing Information, including BOXED WARNING.

Watch medical oncologist Dr Martin Dietrich and gynecologic oncologist Dr Robert Holloway discuss key steps for starting patients on ELAHERE, including dosing and administration, proactive management of ocular events, and available support and resources.

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION

ELAHERE is indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Select patients for therapy based on an FDA-approved test.

IMPORTANT SAFETY INFORMATION

WARNING: OCULAR TOXICITY

● ELAHERE can cause severe ocular toxicities, including visual impairment, keratopathy, dry eye, photophobia, eye pain, and uveitis.
● Conduct an ophthalmic exam including visual acuity and slit lamp exam prior to initiation of ELAHERE, every other cycle for the first 8 cycles, and as clinically indicated.
● Administer prophylactic artificial tears and ophthalmic topical steroids.
● Withhold ELAHERE for ocular toxicities until improvement and resume at the same or reduced dose.
● Discontinue ELAHERE for Grade 4 ocular toxicities.

Please see additional Important Safety Information at https://www.ELAHEREhcp.com/#isi.

Learn more at https://www.ELAHEREhcp.com.

© 2025 AbbVie. All rights reserved.
ELAHERE and its design are trademarks of ImmunoGen, Inc., an AbbVie company.
US-EPROC-250271

Видео Starting patients on a targeted treatment | See abbv.ie/ElaherePI канала ELAHERE® (mirvetuximab soravtansine-gynx) HCP